Highly touted programs sponsored by drug companies in Florida to illustrate the role medicines can play in controlling health care costs failed to save the state enough money to warrant their renewal. Facing soaring drug costs, Florida began demanding rebates from pharmaceutical companies in 2001 to have their medicines included on the preferred list for the state’s Medicaid population.
